Skip to main content
. 2018 Jul 16;9(3):255–263. doi: 10.3892/mco.2018.1672

Figure 2.

Figure 2.

mPFS according to the line of treatment. The mPFS was 11.6 (95% CI, 5.8-17.3), 9.7 (95% CI, 7.7-10.8) and 7.5 (95% CI, 6.0-9.8) months for patients treated with Exe-Eve as first, second or third line of treatment, respectively. mPFS, median progression-free survival; Eve-Exe, Everolimus-Exemestane; CI, confidence interval.